Dr. Reddy’s Laboratories (DRL) has launched Zoledronic Acid injection (5 mg/100 ml), a therapeutic equivalent generic version of Reclast injection, in the U.S. markets on Wednesday.

The launch follows the approval given by the U.S. Food and Drug Administration for Dr. Reddy’s ANDA for Zoledronic Acid injection.

The Reclast brand had total sales (in U.S.) of about $355 million for the 12 months ending February, and the injection would be available in a single use vial for intravenous infusion, says a release.